Table 2.
Characteristics of patients undergoing allo-HSCT
| Patient’ characteristics | Overall (n = 223) | LEVO-group (n = 71) | NO-LEVO-group (n = 152) | P value |
|---|---|---|---|---|
| Baseline | ||||
| Age at allo-HSCT, y, median (IQR) | 56 (41-65) | 52 (38-65) | 57 (44-66) | .20 |
| Male sex | 145 (65%) | 45 (63.4%) | 100 (65.8%) | .72 |
| ANC ≤500 cells/mm3 ≥ 7 d | 28 (12.6%) | 9 (12.7%) | 19 (12.5%) | .97 |
| Diagnosis | .003 | |||
| Myeloid disorders | 164 (73.5%) | 42 (59.2%) | 122 (80.3%) | |
| Lymphoid disorders | 54 (24.2%) | 26 (36.6%) | 28 (18.4%) | |
| Other disorders | 5 (2.3%) | 3 (4.2%) | 2 (1.3%) | |
| Disease status at allo-HSCT | .30 | |||
| Complete response | 140 (62.8%) | 46 (64.8%) | 94 (61.9%) | |
| Active disease and upfront | 78 (35%) | 22 (31%) | 56 (36.8%) | |
| Other | 5 (2.2%) | 3 (4.2%) | 2 (1.3%) | |
| Ongoing line of therapy | .56 | |||
| First line | 99 (44.4%) | 28 (39.4%) | 71 (46.7%) | |
| Second line | 69 (30.9%) | 23 (32.4%) | 46 (30.3%) | |
| ≥Third line | 55 (24.7%) | 20 (28.2%) | 35 (23%) | |
| Total number of allo-HSCT for patient | .15 | |||
| First allo-HSCT | 206 (92.4%) | 62 (87.3%) | 144 (94.7%) | |
| Second allo-HSCT | 15 (6.7%) | 8 (11.3%) | 7 (4.6%) | |
| Third allo-HSCT | 2 (0.9%) | 1 (1.4%) | 1 (0.7%) | |
| HCT-CI index (not age-adjusted) | .36 | |||
| 0-1 | 100 (44.8%) | 35 (49.3%) | 65 (42.8%) | |
| ≥2 | 123 (55.2%) | 36 (50.7%) | 87 (57.2%) | |
| Donor type | .18 | |||
| Matched related donor | 44 (19.7%) | 11 (15.5%) | 33 (21.7%) | |
| Matched unrelated donor | 105 (47.1%) | 33 (46.5%) | 72 (47.4%) | |
| Haploidentical donor | 61 (27.4%) | 25 (35.2%) | 36 (23.7%) | |
| Cord blood | 13 (5.9%) | 2 (2.8%) | 11 (7.2%) | |
| Stem cell source | .41 | |||
| Peripheral blood stem cells | 203 (91%) | 67 (94.4%) | 136 (89.5%) | |
| Bone marrow | 7 (3.1%) | 2 (2.8%) | 5 (3.3%) | |
| Cord blood | 13 (5.8%) | 2 (2.8%) | 11 (7.2%) | |
| Conditioning chemotherapy | .05 | |||
| Myeloablative | 136 (61%) | 50 (70.4%) | 86 (56.6%) | |
| Reduced toxicity | 87 (39%) | 21 (29.6%) | 66 (43.4%) | |
| GVHD prophylaxis | .03 | |||
| PT-Cy/sirolimus–based regimens | 186 (83.4%) | 66 (93%) | 120 (79%) | |
| PT-Cy/ATG or ATG-based regimens | 20 (9%) | 2 (2.8%) | 18 (11.8%) | |
| Other regimens | 17 (7.6%) | 3 (4.2%) | 14 (9.2%) | |
| MDR-GNB rectal carrier within 30 d before allo-HSCT | 9 (4%) | 6 (8.5%) | 3 (2%) | .02 |
| Antibiotics ≤90 d before allo-HSCT | 84 (37.7%) | 26 (36.6%) | 58 (38.2%) | .83 |
| Carbapenems | 43 (51.2%) | 15 (57.7%) | 28 (48.3%) | .48 |
| Fluoroquinolones | 8 (9.5%) | 2 (7.7%) | 6 (10.3%) | 1.00 |
| Glycopeptides | 40 (47.6%) | 15 (57.7%) | 25 (43.1%) | .25 |
| Penicillin/β-lactam inhibitors | 51 (60.7%) | 14 (53.8%) | 37 (63.8%) | .47 |
| Carbapenems or penicillin/β-lactam inhibitors | 68 (81.0%) | 21 (80.8%) | 47 (81.0%) | .99 |
| GNB BSI within 90 d before allo-HSCT | 26 (11.9%) | 5 (7.4%) | 21 (14.0%) | .18 |
| Follow-up | ||||
| Follow-up, days, median (IQR) | 367 (169-685) | 819 (239-966) | 300 (148-526) | <.0001 |
| ANC engraftment | 202 (92.7%) | 64 (90.1%) | 138 (93.9%) | .32 |
| Time to engraftment, d, median (IQR) | 21 (18-28) | 21 (18-28) | 21 (18-28) | .56 |
| Relapse | 39 (17.5%) | 17 (23.9%) | 22 (14.5%) | .08 |
| Time to relapse, d, median (IQR) | 163 (98-335) | 195 (137-368) | 116 (71-227) | .02 |
| Acute GVHD ≥2 | 53 (23.8%) | 13 (18.3%) | 40 (26.3%) | .19 |
| Time to acute GVHD ≥2, d, median (IQR) | 39 (27-54) | 43 (30-61) | 36 (23-49) | .29 |
| Overall death | 56 (25.1%) | 25 (35.2%) | 31 (20.4%) | .02 |
| Time to death, d, median (IQR) | 148 (45-246) | 187 (101-326) | 85 (23-181) | .03 |
| Cause of death | 0.03 | |||
| Disease | 24 (10.8%) | 13 (18.3%) | 11 (7.2%) | |
| IRM | 18 (8.1%) | 5 (7%) | 13 (8.6%) | |
| GVHD | 10 (4.5%) | 6 (8.5%) | 4 (2.6%) | |
| Other | 4 (1.8%) | 1 (1.4%) | 3 (2%) |
ATG, antithymocyte globulin; HCT-CI index, hematopoietic cell transplantation comorbidity index; PT-Cy, posttransplant cyclophosphamide.